Adaptimmune Therapeutics Plc Valor Contábil/Ação
Qual é o Valor Contábil/Ação de Adaptimmune Therapeutics Plc?
O Valor Contábil/Ação de Adaptimmune Therapeutics Plc é 0.19
Qual é a definição de Valor Contábil/Ação?
O valor contábil por ação é um ativo da empresa menos as responsabilidades dividido pelo número de ações em circulação.
The book value of a company is the value of its assets according to its balance sheet account balance. For assets, the value is based on the original cost of the asset less any depreciation, amortization or impairment costs made against the asset. Traditionally, a company's book value is its total assets minus intangible assets and liabilities. However, in practice, depending on the source of the calculation, book value may variably include goodwill, intangible assets, or both. The value inherent in its workforce, part of the intellectual capital of a company, is always ignored. The book value of a company may be also referred as with the term net asset value.
The book value per share is the the balance sheet equity value divided by the number of shares outstanding at the date of the balance sheet. Book value per share can be used to generate a measure of comprehensive earnings, when the opening and closing values are reconciled. The sale of shares/units by a business increases the total book value. Book value per share will increase if the additional shares are issued at a price higher than the pre-existing book value per share. The purchase of its own shares by a business will decrease total book value. Book value per share will decrease if more is paid for them than was received when originally issued. Dividends paid out will decrease book value per share value.
Valor Contábil/Ação de empresas na Setor Health Care em NASDAQ em comparação com Adaptimmune Therapeutics Plc
O que Adaptimmune Therapeutics Plc faz?
adaptimmune llc is a multinational, clinical-stage biopharmaceutical company focused on developing novel immunotherapies using its proprietary t-cell receptor platform that has the potential to transform the treatment of cancer. established in 2008, the company has grown from being privately held to one of the most successful biopharmaceutical initial public offerings (ipo) in 2015. with u.s. operations based in philadelphia, pa, adaptimmune is a company founded on strong science that has led to a robust pipeline of immuno-oncology product candidates, a growing research & development platform and ongoing plans for expansion. for more information about adaptimmune, please visit www.adaptimmune.com. if interested in joining our fast growing team, click on the careers tab of this page.
Empresas com valor contábil/ação semelhantes a Adaptimmune Therapeutics Plc
- Red 5 tem Valor Contábil/Ação de 0.19
- Whispir tem Valor Contábil/Ação de 0.19
- Thunderbird Resorts tem Valor Contábil/Ação de 0.19
- Kutcho Copper tem Valor Contábil/Ação de 0.19
- Tisdale Resources tem Valor Contábil/Ação de 0.19
- WAC tem Valor Contábil/Ação de 0.19
- Adaptimmune Therapeutics Plc tem Valor Contábil/Ação de 0.19
- RENHENG Enterprise tem Valor Contábil/Ação de 0.19
- Tysan tem Valor Contábil/Ação de 0.19
- Synairgen plc tem Valor Contábil/Ação de 0.19
- Ambition tem Valor Contábil/Ação de 0.19
- Stuhini Exploration tem Valor Contábil/Ação de 0.19
- Ethos Gold tem Valor Contábil/Ação de 0.19